Heli Tuppurainen
A5086426894- Schizophrenia research and treatment
- Functional Brain Connectivity Studies
- Transcranial Magnetic Stimulation Studies
- Genetic Associations and Epidemiology
- Treatment of Major Depression
- Psychiatric care and mental health services
- Bipolar Disorder and Treatment
- Healthcare Decision-Making and Restraints
- Mental Health and Psychiatry
- Advanced Neuroimaging Techniques and Applications
- Neurotransmitter Receptor Influence on Behavior
- Muscle activation and electromyography studies
- Pharmacovigilance and Adverse Drug Reactions
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Advanced MRI Techniques and Applications
- Advanced Causal Inference Techniques
- Pharmaceutical Practices and Patient Outcomes
- Anesthesia and Sedative Agents
- Neurological disorders and treatments
- Neural and Behavioral Psychology Studies
- Neural dynamics and brain function
- Cardiovascular Syncope and Autonomic Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Mental Health Treatment and Access
University of Eastern Finland
2003-2025
Niuvanniemi Hospital
2006-2025
Folkhälsans Forskningscentrum
2024
Kuopio University Hospital
2017-2024
Stockholm County Council
2024
Karolinska Institutet
2024
An abstract is not available for this content so a preview has been provided. As you have access to content, full PDF via the 'Save PDF' action button.
Abstract Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. However, response highly variable and possible genetic underpinnings of this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate amount variance in symptom severity among clozapine-treated explained by PRSs (R2) examined association between genotype-predicted CYP1A2, CYP2D6, CYP2C19 enzyme activity. Genome-wide (GWA) were explore loci...
Clozapine is often underused due to concerns about adverse drug reactions (ADRs) but studies into their prevalences are inconclusive. We therefore comprehensively examined of clozapine-associated ADRs in individuals with schizophrenia and demographic clinical factors associated occurrence. Data from a multi-center study (n=698 participants) were collected. The mean number during clozapine treatment was 4.8, 2.4% participants reporting no ADRs. most common hypersalivation (74.6%), weight gain...
Guidelines issued by professional organizations recommend that all patients with psychotic disorders who have had several relapses, continue maintenance anti-psychotic treatment. However, some discontinue anti-psychotics and do not later relapse. This study attempted to characterize those early in their disease taking antipsychotics, were hospitalized. population-based cohort combined registry data on diagnosed first episode (ICD 10 code: F20-29) from Sweden (n = 20 848), Israel 045),...
Predictors consistently associated with psychosis liability and course of illness in schizophrenia (SCZ) spectrum disorders (SSD), including the need for clozapine treatment, are lacking. Longitudinally ascertained medication use may empower studies examining associations between polygenic risk scores (PRSs) pharmacotherapy choices.To examine PRS-SCZ loading groups different liabilities to SSD (individuals taking clozapine, individuals other antipsychotics, their parents siblings, unrelated...
<h3>Background:</h3> Previous electroencephalography (EEG) studies have indicated altered brain oscillatory α-band activity in schizophrenia, and treatment with repetitive transcranial magnetic stimulation (rTMS) using individualized α-frequency has shown therapeutic effects. Magnetic resonance imaging–based neuronavigation methods allow of a specific cortical region improve targeting rTMS; therefore, we sought to study the efficacy navigated, individual α-peak-frequency–guided rTMS (αTMS)...
Clozapine is highly effective for treatment-resistant schizophrenia but underutilized due to patient and clinician-related concerns. Little known about the general level of satisfaction with clozapine determinants thereof. We therefore explored in individuals diagnosed spectrum disorders (SSDs). Cross-sectional data from 480 users were used examine demographic clinical factors, including symptom severity, treatment response, adverse drug reactions (ADRs). Patient was self-rated on a scale 1...
Aberrant dopamine transmission in extrastriatal brain regions has been repeatedly illustrated among patients with schizophrenia. Differences between typical and second-generation antipsychotics D(2) receptor modulation within various areas remain a topic for debate. The aim of the present study was therefore to investigate D(2/3) apparent binding potential (BP(app)) occupancy midbrain temporal cortex clozapine-, olanzapine- haloperidol-treated schizophrenia patients.Dopamine studied on...
Background: The exact mechanisms for antipsychotic-induced extrapyramidal side-effects have remained obscure despite intensive research. Previous studies highlighted a central role nigral dopamine D2 receptors in the control of motor functions. Aims: aim present study was to examine relationships between receptor binding both substantia nigra and temporal cortex with symptoms among antipsychotic-treated patients schizophrenia. Methods: Single-photon emission-computed tomography (SPECT)...
Abstract Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. However, response highly variable and possible genetic underpinnings of this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate amount variance in symptom severity among clozapine-treated explained by PRSs (R2) examined association between genotype-predicted CYP1A2, CYP2D6 , CYP2C19 enzyme activity. Genome-wide (GWA) were explore loci...